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Abstract
Background: Pulmonary hypertension (PH) results in severely impaired quality of life (QoL) in people 
with this condition. The CAMbridge Pulmonary Hypertension Outcome Review (CAMPHOR) is the 
only questionnaire providing a disease-specific measurement of symptoms, functioning and QoL in PH 
patients. It has already been adapted for use in several countries. The aim of this study was to adapt 
and validate CAMPHOR for the Polish-speaking population.
Methods: Two panels (bilingual and lay) were conducted to translate CAMPHOR into Polish. This new 
version was then tested by cognitive debriefing interviews with 15 patients. Finally, a postal validation 
survey was conducted with 56 patients on two occasions 2 weeks apart to assess its psychometric properties. 
Results: No problems were experienced in producing a Polish translation of CAMPHOR. Interviewees 
responded well to the Polish CAMPHOR, finding it relevant, comprehensible and easy to complete. For 
all three CAMPHOR scales (Symptoms, Activity, QoL), The Cronbach alpha coefficients were above 
0.8 at both time points, indicating high internal consistency. Test-retest reliability for the three scales 
achieved a value above 0.80. Predicted correlations with the Nottingham Health Profile provided evi-
dence of the construct validity of CAMPHOR scales. The Polish CAMPHOR could distinguish between 
patients who differed according to their perceived general health and perceived disease severity. No 
significant differences in scores were found between participants grouped by gender or age.
Conclusions: The Polish version of CAMPHOR demonstrated good psychometric properties and is 
recommended for use in clinical practice. (Cardiol J XXXX; XX, X: xx–xx)
Key words: adaptation, CAMPHOR, quality of life, patient reported outcome,  
pulmonary hypertension
Introduction
Precapillary pulmonary hypertension (PH) is 
a condition, when mean pulmonary artery pressure 
increases significantly (≥ 25 mmHg) whereas the 
capillary wedge pressure remains within normal 
values (≤ 15 mmHg). It is represented in the clini-
cal classification as group 1 — pulmonary arterial 
hypertension (PAH), group 3 — PH due to lung 
diseases and/or hypoxia, and group 4 — chronic 
thromboembolic PH (CTEPH). In Poland, the 
prevalence of PAH in adults is about 19.6 cases 
per million population. The number of patients 
increases year by year, suggesting that the disease 
is becoming better diagnosed [1]. A number of 
trials are in progress to improve life expectancy 
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in this disease. However, the main problems that 
investigators face in planning such trials is a lack 
of ideal endpoints [2]. 
Recent clinical studies have assessed Health 
Related Quality of Life (HRQL) using generic 
patient-reported outcome measures, such as the 
SF-36 [3–5], EuroQol [6, 7] and Nottingham Health 
Profile [8]. HRQL provides information that is of 
interest to clinicians with a focus on symptoms and 
functional limitations resulting from a disease [9]. 
However, these measures demonstrate relatively 
low responsiveness, especially with PH patients 
[10]. For example, to obtain a minimally important 
difference on the SF-36 domains, scores must im-
prove between 13 and 25 points on a scale  of 0–100. 
A modified version of the Minnesota Living with 
Heart Failure Questionnaire [11, 12] has also been 
used [13, 14]. However, the questionnaire was not 
designed for patients with PH and so it cannot be 
concluded that changes in score are valid.
Comprehensive disease-specific measures 
that directly address PH characteristics are re-
quired. The CAMbridge Pulmonary Hypertension 
Outcome Review (CAMPHOR) is the first disease-
specific questionnaire to assess both health-related 
QoL (symptoms and activity limitations) and QoL 
in patients diagnosed with PH [15]. CAMPHOR 
consists of three sections; symptoms (25 items), 
activities (15 items) and QoL (25 items). Quality of 
life is concerned with measuring how these symp-
toms and functioning affect the lives of patients, for 
example, whether they are able to fulfil their roles 
in life, communicate with others or interact socially. 
The measurement model, the needs-based model 
of QoL, argues that quality of life is the extent to 
which an individual is able to meet his or her basic 
human needs [16].
CAMPHOR is widely used in international 
clinical studies for evaluating the benefits patients 
gain from alternative treatments for the condition. 
It is also used to monitor the progress as well as 
response to treatment of individual patients in 
clinical practice. It is an outcome measure that 
shows the effects of treatment from the viewpoint 
of the patient. Research has shown that CAMPHOR 
scales are responsive to change, with effect sizes 
ranging from 0.31 to 0.69. It should be noted that 
CAMPHOR is at least as responsive as the 6-min 
walking test. This is often used as a primary end-
point in clinical trials, having demonstrated effect 
sizes that range from 0.16 to 0.34 [17].
CAMPHOR was developed in the United 
Kingdom (UK) and has since been adapted into 18 
additional languages [18–25]. This report describes 
the adaptation of CAMPHOR into Polish and in-
cludes results from the translation, field-testing 
and psychometric evaluation of the new language 
version. A successful adaptation would provide a 
valid and reliable outcome measure for use in PH 
clinical practice and trials in Poland. 
Methods
The process of adaptation of CAMPHOR 
questionnaire consisted of three main stages: 
translation (by means of a bilingual and lay panel), 
cognitive debriefing interviews with patients and 
a postal validation survey. Local ethics committee 
at Poznan University of Medical Sciences approved 
the study (resolution No. 728/16).
Stage 1: Translation process
The dual-panel methodology was used to 
translate CAMPHOR into Polish [26]. The bilin-
gual translation panel consisted of 5 native Polish 
speakers (3 females and 2 males; aged from 26 to 
51 years) with competence in English at the C2 
level (proficient user) according to the Common 
European Framework of Reference for Languages 
(CEFR). They were asked to translate the UK 
English CAMPHOR into Polish, while keeping 
the following requirements in mind: capturing the 
same concepts as the original version and produc-
ing a comprehensible formulation of the concepts. 
Conceptual equivalence is of primary importance 
in this methodology. All items were discussed until 
an agreement was reached. A separate lay panel 
consisted of 5 monolingual Polish participants (4 
females and 1 male; aged from 22 to 48 years). 
Individuals included to the lay panel were of an 
average to lower than average education level to 
ensure that the wording of the questionnaire is at 
an appropriate level for typical patients. Partici-
pants were presented with the translations made 
by the bilingual panel and asked to decide whether 
the phrasing and language were acceptable and 
sounded ‘natural’. The purpose of this second 
panel was to ensure that the wording of items was 
appropriate to respondents from all educational 
backgrounds. The lay panel was provided with 
alternative formulations of items in which a con-
sensus could not be reached by the bilingual panel 
participants.
Stage 2: Cognitive debriefing interviews
Cognitive debriefing interviews were con-
ducted with PH patients from Warsaw. The patients 
were recruited through convenience sampling 
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from a single center. Eleven of the interviewees 
had idiopathic pulmonary arterial hypertension 
(IPAH), one chronic thromboembolic pulmonary 
hypertension (CTEPH), one had PH associated 
with scleroderma and two had congenital heart 
disease. The aim of these interviews was to check 
the applicability, comprehension, relevance and 
comprehensiveness of the translated scales with 
appropriate patients. The semi-structured inter-
views were conducted face-to-face. Respondents 
completed the questionnaire in the presence of an 
interviewer and were then asked to answer specific 
questions about the measure. 
Stage 3: Validation
To further validate the Polish version of CAM-
PHOR, PH patients of mixed etiology treated in 1st 
Department of Cardiology, Poznan, Poland in 2016 
were recruited. Pulmonary hypertension was diag-
nosed according to the standard criteria [27] and 
confirmed by right heart catherization. Detailed 
demographic and disease information is shown in 
Table 1. The CAMPHOR was administered twice 
by mail approximately 2 weeks apart. Patients also 
completed the Nottingham Health Profile ques-
tionnaire (NHP) [27] at the first administration. 
Demographic (sex, age, marital status, occupation) 
and disease information (time since diagnosis, 
perceived general health and disease severity) 
was also collected. 
Statistical analyses
Non-parametric statistical tests were used 
throughout the analyses due to the ordinal nature of 
the data. Internal consistency of CAMPHOR scales 
was evaluated by determining the Cronbach alpha 
coefficients. Test-retest reliability was examined 
using the Spearman rank correlation coefficients. 
Convergent validity was assessed by comparing 
scores on CAMPHOR scales with those on the 
NHP sections.
Known-group validity is the ability to distin-
guish between groups of patients who differ accord-
ing to some known factor. The following variables 
were used for this purpose: patient-perceived 
general health (very good/good/fair/poor) and 
patient-perceived disease severity (mild/moderate/
quite severe/very severe). P-values < 0.05 were 
considered statistically significant.
Outcome measures
CAMPHOR. The CAMPHOR was originally 
developed and validated in the United Kingdom 
[15]. It consists of a 25-item symptom scale (scored 
0–25), a 15-item functioning scale (scored 0–30) 
and a 25-item QoL scale (scored 0–25). For all 
scales, a low score indicates better status. All vali-
dated language versions demonstrate good internal 
consistency, reproducibility and validity [18–25].
Nottingham Health Profile. The NHP is 
a 38-item questionnaire of perceived distress that 
has been widely used in health research [28]. It 
Table 1. Demographic and disease information 
of the validation sample (n = 56).
Age [years]
Median 57.1
IQR 43.6–69.1
Gender
Male 17 (30.4%)
Female 39 (69.6%)
Marital status
Married/Living as married 33 (58.9%)
Divorced 5 (8.9%)
Widowed 8 (14.3%)
Single 10 (17.9%)
Work status
Full-time 4 (7.1%)
Part-time 1 (1.8%)
Retired 21 (37.5%)
Homemaker 5 (8.9%)
Long-term sick leave 18 (32.1%)
Student 2 (3.6%)
Unemployed 5 (8.9%)
Cause of PH
Idiopathic PAH 17 (30.4%)
Associated PAH 18 (32.1%)
Connective tissue disease 4 (7.1%)
Congenital heart disease 14 (25.0%)
CTEPH 21 (37.5%)
Patient-perceived general health
Very good 1 (1.8%)
Good 19 (33.9%)
Fair 24 (42.9%)
Poor 12 (21.4%)
Patient-perceived disease severity 
Mild 2 (3.6%)
Moderate 11 (19.6%)
Quite severe 32 (57.1%)
Very severe 11 (19.6%)
CTEPH — chronic thromboembolic pulmonary hypertension;  
IQR — interquartile range; PAH — pulmonary arterial hypertension; 
PH — pulmonary hypertension
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includes 6 sections, evaluating: energy level, pain, 
emotional reactions, sleep, social isolation and 
physical mobility. All sections are scored 0 to 100 
with a lower score indicative of better health status. 
Results
Translation
No significant difficulties were present during 
the translation process. In the adaptation process 
every additional step checks the correctness of pre-
vious stages and the results of the postal validation 
survey demonstrate whether the newly adapted 
version is reliable and valid. Therefore, no other 
investigations were required. Additionally, it is pos-
sible that certain words or concepts could not have 
been translated in a reasonable way however we did 
not find this to be the case. Where more than one 
translation was proposed by the bilingual panel, the 
lay panel generally reached agreement with little 
discussion. For example, the lay panel felt that the 
translation “Mam dosyć swojej choroby” expressed 
the feeling of being fed up more clearly than the 
alternative “Jestem zmęczony moją chorobą”. For 
the item ‘I feel guilty asking for help’, the bilingual 
panel suggested three translations (“Czuję się źle/
zawstydzony/zażenowany, prosząc o pomoc”). The 
lay panel considered that “zawstydzony” could be 
misinterpreted as meaning shyness, while the word 
“zażenowany” was thought to be too complicated. 
Therefore, the panel agreed that “źle” was the most 
appropriate translation for this item. 
Cognitive debriefing interviews
Fifteen cognitive debriefing interviews were 
conducted with patients. All patients understood 
clearly the purpose of the interview. Most of the 
patients responded well to the questionnaire, they 
thought it was simple and easy to complete. The 
items were clear and comprehensible. Interview-
ees felt that the items reflected their situation well, 
that they could relate to the ideas expressed and 
felt that no part of their experience of PH was miss-
ing. No changes were made to the questionnaire 
as a result of the cognitive debriefing interviews.
Validation
Fifty-seven participants were recruited at 
Time 1. Of these 56 (98.2%) patients completed 
and returned the questionnaire at Time 2. Table 2 
shows descriptive statistics for the questionnaires 
at both time points. High floor effects (high number 
of patients scoring the minimum) were observed for 
most NHP sections. This indicates that the NHP 
is not well targeted to PH patients in this sample.
Internal consistency
For all CAMPHOR scales, the Cronbach alpha 
coefficients were above 0.8, indicating high internal 
consistency (Table 3). 
Table 2. Questionnaires descriptive statistics. 
N Median Interquartile 
range
Minimum– 
–Maximum
% scoring  
minimum
% scoring  
maximum
CAMPHOR Time 1
Symptoms 56 11 7–18 0–25 3.6 1.8
Activities 55 9 6–13 0–22 3.6 0
QoL 56 8 3–13 0–25 5.4 3.6
NHP Time 1
Energy 53 33.3 0–100 0–100 28.6 26.8
Pain 52 12.5 0–25 0–100 42.9 1.8
Emotional reactions 53 22.2 0–44.4 0–100 33.9 3.6
Sleep 53 40 0–80 0–100 30.4 10.7
Social isolation 53 0 0–20 0–80 62.5 0
Physical mobility 51 37.5 12.5–50 0–87.5 12.5 0
CAMPHOR Time 2
Symptoms 56 10.5 6–16 0–25 5.4 1.8
Activities 56 11.5 7–14.8 0–23 3.6 0
QoL 56 8 3–13.8 0–25 7.1 1.8
NHP — Nottingham Health Profile; QoL — quality of life
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Test-retest reliability
Test-retest reliability for the three scales was 
0.81 for Symptoms, 0.89 for Activities and 0.96 
for QoL. These values suggest that the measure 
produces low levels of measurement error.
Convergent validity 
Evidence of convergent validity can be seen 
in Table 4 where significant correlations between 
scores on CAMPHOR and NHP sections at Time 
1 are shown. 
Association with demographic factors 
Table 5 shows CAMPHOR scores for patients 
grouped by gender and age (below vs. above me-
dian age). No significant differences in CAMPHOR 
scores were found between participants grouped by 
gender. The Mann-Whitney U test revealed there 
was a significant difference found between older 
and younger individuals for CAMPHOR Activities 
and QoL scales. Older patients had significantly 
worse scores on these two scales compared to 
younger patients. The c2 test of independence was 
performed to investigate age differences in greater 
detail. A significant association was found between 
age and perceived disease severity (c² (1) = 4.9, 
p = 0.04). Similarly, a significant relation was found 
between age and perceived general health (c² (1) = 
= 7.8, p = 0.008). 
Known group validity
Mann-Whitney U tests demonstrated statisti-
cally significant differences in CAMPHOR scores 
between patients who differed according to their 
perceived general health (Fig. 1) and disease se-
verity (Fig. 2). 
Patients who rated their disease severity as quite 
or very severe had significantly worse scores on all 
CAMPHOR scales than patients who rated their dis-
ease severity as mild or moderate. Respondents who 
Table 3. Cronbach’s alpha coefficients at Time 1 
and Time 2.
CAMPHOR Time 1 Time 2
Symptoms 0.94 0.92
Activities 0.89 0.91
QoL 0.94 0.94
Table 4. Correlation coefficients between CAMPHOR scale scores and Nottingham Health Profile (NHP) 
section scores.
NHP Symptoms Activities Quality of life
Energy 0.75 0.55 0.72
Pain 0.48 0.43 0.48
Emotional reactions 0.54 0.23* 0.72
Sleep 0.39 0.05* 0.45
Social isolation 0.48 0.19* 0.58
Physical mobility 0.69 0.86 0.70
Note: p = 0.01 (2-tailed) for all correlations except where marked. *Correlation is not significant at 0.05 level (2-tailed).
Table 5. Median scores by demographic factors
Symptoms Activities QoL
N Median (IQR) N Median (IQR) N Median (IQR)
Gender
Male 17 10.0 (7.0–17.5) 17 10.0 (7.0–15.0) 17 8.0 (3.5–15.5)
Female 39 11.0 (6.0–19.0) 38 8.5 (5.8–12.3) 39 8.0 (3.0–11.0)
P 56 0.80 55 0.22 56 0.46
Age
Below median 28 10.5 (3.3–17.8) 28 7.0 (5.0–10.8) 28 5.5 (2.0–10.5)
Above median 28 11.0 (7.3–19.8) 27 12.0 (8.0–15.0) 28 9.0 (5.0–15.8)
P 56 0.30 55 0.008 56 0.04
P value (2-tailed); IQR — interquartile range; QoL — quality of life
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considered their general health to be fair or poor had 
significantly worse CAMPHOR scores than patients 
who rated their health as good or very good. This 
demonstrates the ability of the Polish CAMPHOR 
to detect meaningful differences.
Discussion
This study shows that the Polish adaptation 
of CAMPHOR was successful. The new language 
version meets the expectations of good internal 
consistency, test-retest reliability, and convergent 
and known group validity. Similar findings have 
been reported for previous adaptations of the 
CAMPHOR [18–25]. 
Translations that are conceptually equivalent 
make it possible to compare scores across coun-
tries and to combine data from different countries 
in international clinical trials [14]. The dual panel 
methodology was applied. The translation methodol-
ogy used in the adaptation of CAMPHOR has been 
shown to produce more acceptable translations and 
this method is preferred in the adaptation of all need-
based measures [29]. Moreover, this method places 
great emphasis on achieving conceptual equivalence 
of translated items to the original. It is important 
that translated items are expressed in everyday 
language, so that they are easily understood by 
future respondents, which is why the lay panel is 
used. In the next stage of adaptation, patients with 
PH in cognitive debriefing interviews confirmed the 
ease of answering particular items and no additional 
changes were necessary.. Furthermore, the use of a 
postal system at the validation stage was preferred, 
because the CAMPHOR is a patient-reported ques-
tionnaire, so adding an interviewer might have 
introduced response bias.
In an evaluation of internal consistency, coef-
ficients of all three CAMPHOR scales (Symptoms, 
Activities and QoL) were above 0.8, indicating high 
internal consistency. Moreover, high test-retest 
coefficients obtained in all CAMPHOR scales 
confirmed its reproducibility. NHP was used in the 
validation of the original UK English CAMPHOR 
[15] and was adapted and validated in Polish for use 
as a comparator measure in the study of McKenna 
et al. [30]. The Polish NHP was developed using 
the same methodology as the Polish CAMPHOR. 
CAMPHOR consists of three separate sections 
measuring different types of outcomes: symptoms 
(impairment), activity limitations (disability) and 
QoL. The relations between scores on NHP energy 
section and all three CAMPHOR scales reflect the 
nature of the disease. Physical mobility (disability) 
was highly related to CAMPHOR disability and 
also had an overall impact on QoL scores. Overall, 
QoL scores were most influenced by energy level, 
emotional reactions and physical mobility. These 
results were both expected and matched findings 
from previous CAMPHOR adaptations [21, 23–25].
The Polish CAMPHOR scales were able to 
differentiate clearly between groups of patients 
depending on their perceived general health and 
perceived disease severity. The finding that older 
individuals reported significantly worse scores on 
the Activities and QoL scales was explored further. 
Investigation of the age differences revealed that 
older participants experience significantly worse in 
perceived disease severity and perceived general 
Figure 2. Median CAMPHOR scale scores by perceived 
disease severity. Note: Activities and quality of life (QoL) 
comparisons significant at p < 0.01 (2-tailed). Symp-
toms scale comparisons significant at p < 0.05 (2-tailed).
Figure 1. Median CAMPHOR scale scores by perceived 
general health. Note: All comparisons significant at 
p < 0.01 (2-tailed); QoL — quality of life.
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health compared to younger individuals. This is 
in line with previous research that found physical 
functioning worsened with age in PH patients [31]. 
Quality of life assessment can serve as an 
important endpoint especially in patients with an 
incurable disease. It differs from HRQL in that it 
assesses outcomes that are of relevance and interest 
to patients rather than physicians [9]. Carefully de-
veloped QoL scales provide a holistic picture of the 
impact of disease and its treatment on the patient. 
In the case of chronic or terminal illness where no 
effective cure is available, emphasis should be placed 
on improving QoL as the goal of treatment [9].
The Polish CAMPHOR can be applied in both 
research and clinical settings in the Polish PH 
population. Previous research has shown that some 
endpoints do not indicate how patients respond to 
the illness [14]. This means that it is not possible 
to determine which interventions are of greatest 
value to them. Therefore, the wide range of issues 
covered by the CAMPHOR may support clinicians 
in the management and monitoring of patients.
Limitations of the study
A limitation of this study is the sample size. 
However, it was designed to establish the suitabil-
ity of the Polish CAMPHOR rather than to describe 
in detail the impact of PH on patients. 
Conclusions
The psychometric properties of the Polish 
version of CAMPHOR indicates that it is a valid 
and reliable measure of both HRQL and QoL in 
patients with PH. The new language version is 
recommended for use in the Polish population who 
speak Polish.
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